Regulatory Publishing

Expert Regulatory Publishing to Support Successful eCTD Submissions

Our regulatory publishing team will support the publishing of your regulatory applications, amendments, supplements and reports to the United States Food and Drug Administration (FDA) through the Electronic Submissions Gateway (ESG).  Currently, the FDA requires most regulatory submissions to be submitted in eCTD format, which improves the efficiency of delivery, formatting, and review of the submission files.

Oversight, Expertise, and Ability to Successfully Publish eSubmissions to the FDA

Due to increasing regulatory agency requirements, Veristat delivers regulatory publishing support as part of our regulatory application solution.  Our clients benefit from having end-to-end services – the same team works on your program from a regulatory, CMC and clinical perspective, writes your regulatory documents, and then submits them through the ESG to the FDA.

Our publishing experts provide:

  • Project and timeline management for the regulatory publishing process
  • Conversion from paper submissions to eCTD format
  • Use of standardized templates
  • Document level publishing
    • Word formatting: styles, captions, cross-references, tables, etc.
    • Conversion of files to required standards
    • PDF processing: bookmarks, internal links, PDF properties, QC
  • Submission level publishing: eCTD placement, cross-document links, study tagging files (STF)
  • Submission quality control (QC)
  • Transmission of submissions to FDA via Electronic Submissions Gateway
  • Archive and document transfer: archival of final word docs and submission sequence

AS OF MAY 5, 2017,
the following submission types must be submitted electronically:

  • New Drug Application (NDA)
  • Biologics License Application (BLA)
  • Abbreviated New Drug Application (ANDA)

AS OF MAY 5, 2018,
the requirement for electronic submission also included:

  • Commercial Investigational New Drug Application (IND)1
  • Master Files (DMF; Except Type III)

AS OF MAY 5, 2019
Type III DMFs must be submitted through the ESG

 Electronic Regulatory Publishing Expertise  

Types of Regulatory Applications Published

Our publishing team is ready to publish the following regulatory documents to the FDA:

  • Original Dossiers 
    • Investigational New Drug Application (IND)
    • New Drug Application (NDA)
    • Biologics License Application (BLA)



  • All Submission Supporting Documentation
    • Protocol Amendments
    • Investigator Documents
    • Expedited Pathway Submissions
    • Annual Reports, and more
  • DMFs

Learn More with These Resources


Why and When to Hold a Pre-IND Meeting with FDA

While a pre-IND Meeting with the FDA is optional, the Regulatory team at Veristat highly recommends that all
drug developers planning to submit an IND to the FDA have a ...



Similarities and Differences Between the CTA and IND

Suppose the goal of a development program is to initiate clinical trials within European member states, the United Kingdom, or North America. In
that case, strategic ...


Case Study

First Gene Therapy Approved in Europe

Veristat was brought in to create and manage a full development program for a gene therapy for a very rare inherited disorder. The work involved charting the course in ...

Request A Proposal